Document:

Award Letter from Neuromed Pharmaceuticals to Christopher C. Gallen

 Exhibit 10.43 
 

 
 June 17, 2009 
 Six Tower
Bridge, Suite 440 
 181 Washington Street 
 Conshohocken, PA
19428 
 Dear Chris Gallen: 
  

	Re:	EXALGO Approval Bonus 

 With the approval of the Board of
Directors, Neuromed Pharmaceuticals [Inc. / Ltd.] (“Neuromed”) has agreed to grant you a one-time bonus payment in the amount of $250,000 (the “EXALGO Bonus”). 
 Upon receipt by Neuromed of an Additional Milestone Payment under the Asset and Purchase Agreement between Mallinckrodt Inc. and Neuromed Development
Inc. dated June 12, 2009, you will be paid, within 5 business days, the EXALGO Bonus less applicable payroll taxes and deductions. However, the payment of any bonus is contingent upon approval of EXALGOTM hydromorphone by the FDA on or before September 30, 2010. For greater certainty, Neuromed will not pay you the
EXALGO Bonus if approval of EXALGOTM hydromorphone by the FDA is on or after
October 1, 2010. 
 The EXALGO Bonus is a retention bonus and is payable to you if you remain continuously employed by Neuromed
through to approval of EXALGOTM hydromorphone., provided, however, that if Neuromed
terminates your employment without cause, as defined in your employment agreement, you will remain eligible for the EXALGO Bonus upon approval of EXALGOTM hydromorphone. For greater certainty, you will not be eligible for the EXALGO Bonus if your employment is terminated for cause or
if you voluntarily resign your employment prior to approval of EXALGOTM
hydromorphone. 
 This obligation shall not be assignable to any third party without your prior written consent. Notwithstanding the foregoing, a party may
assign this Agreement, without your written consent, (a) to an affiliate, provided that the assigning party guarantees the performance of this agreement by such affiliate, or (b) to a successor to all or substantially all of such assigning
party’s stock or the relevant portion of its assets or business (whether by stock purchase, asset purchase, merger or otherwise), provided that any such assignee agrees in writing to be bound by the terms of this Agreement. 

 You agree that you will not disclose this Agreement or any of its terms, except to members of your immediate family and
to your legal and tax advisors. Please acknowledge the terms of this Agreement by signing below and returning one copy to Victor Urban. 
  

	
	Kind regards,
	
	/s/ Kurt C. Wheeler
	Neuromed Pharmaceuticals Inc.

 ACCEPTED AND AGREED TO THIS 19 DAY OF June, 2009: 
  

	
	 /s/ Chris Gallen

	Chris Gallen
	President and Chief Executive OfficerAward Letter from Neuromed Pharmaceuticals to C. Eugene Wright

 Exhibit 10.44 
 

 
  

			
	 June 17, 2009
	 	 Christopher Gallen, MD, PhD
 DIRECT TELEPHONE: 484.533.6901
 E-MAIL:
cgallen@neuromed.com

 Six Tower Bridge, Suite 440 
 181 Washington Street 
 Conshohocken, PA 19428 
 Dear
Gene Wright: 
  

	Re:	EXALGO Approval Bonus 

 With the approval of the Board of
Directors, Neuromed Pharmaceuticals [Inc. / Ltd.] (“Neuromed”) has agreed to grant you a one-time bonus payment in the amount of $150,000 (the “EXALGO Bonus”). 
 Upon receipt by Neuromed of an Additional Milestone Payment under the Asset and Purchase Agreement between Mallinckrodt Inc. and Neuromed Development
Inc. dated June 12, 2009, you will be paid, within 5 business days, the EXALGO Bonus less applicable payroll taxes and deductions. However, the payment of any bonus is contingent upon approval of EXALGOTM hydromorphone by the FDA on or before September 30, 2010. For greater certainty, Neuromed will not pay you the
EXALGO Bonus if approval of EXALGOTM hydromorphone by the FDA is on or after
October 1, 2010. 
 The EXALGO Bonus is a retention bonus and is payable to you if you remain continuously employed by Neuromed
through to approval of EXALGOTM hydromorphone., provided, however, that if Neuromed
terminates your employment without cause, as defined in your employment agreement, you will remain eligible for the EXALGO Bonus upon approval of EXALGOTM hydromorphone. For greater certainty, you will not be eligible for the EXALGO Bonus if your employment is terminated for cause or
if you voluntarily resign your employment prior to approval of EXALGOTM
hydromorphone. 
 This obligation shall not be assignable to any third party without your prior written consent. Notwithstanding the foregoing, a party may
assign this Agreement, without your written consent, (a) to an affiliate, provided that the assigning party guarantees the performance of this agreement by such affiliate, or (b) to a successor to all or substantially all of such assigning
party’s stock or the relevant portion of its assets or business (whether by stock purchase, asset purchase, merger or otherwise), provided that any such assignee agrees in writing to be bound by the terms of this Agreement. 

 You agree that you will not disclose this Agreement or any of its terms, except to members of your immediate family and
to your legal and tax advisors. Please acknowledge the terms of this Agreement by signing below and returning one copy to Victor Urban. 
  

	
	Kind regards,
	
	/s/ Christopher Gallen, MD, PhD
	  
 Christopher Gallen, MD, PhD
 President & CEO

  
 ACCEPTED AND AGREED TO THIS 18 DAY OF
June, 2009: 
  

	
	 /s/ C. Eugene Wright, III

	Signature of EmployeeRevised Offer Letter from Neuromed Pharmaceuticals - Christopher C. Gallen

 Exhibit 10.45 
 

 
 May 27, 2004 
 Christopher C.
Gallen, M.D., PhD 
 500 Arcola. Road 
 Collegeville, PA. 19426

 REVISED OFFER LETTER 
 Dear Chris, 
 As you are no doubt aware, all of us have greatly enjoyed our interaction with you and have developed a deep respect for your talents. As such we are delighted to convey
this offer to join Neuromed Pharmaceuticals as its President and Chief Executive Officer. We believe that you will be an outstanding CEO and that Neuromed, based on your leadership and talents, has the potential to create tremendous value. On behalf
of the company’s Board of Directors, we sincerely look forward to working with you and would like to officially extend an offer of employment to you to become the President and Chief Executive Officer of Neuromed and a member of the Board of
Directors. The terms in this letter will serve as the basis for a formal Employment Agreement to be prepared and signed as soon as practicable. 
 As Chief
Executive Officer you will be responsible for all facets of the company’s operations, including research and development, finance, business development, human resources, regulatory affairs and, eventually sales, marketing and manufacturing. It
is an exciting time to lead this company, given the opportunities that the company is addressing. We understand that you will relocate the headquarters of Neuromed to the Philadelphia area. In your role as CEO, you will report to the Board of
Directors. All corporate officers will report to you as CEO. You would be expected to structure the management team as you see fit, and subject to consultation with the Board, would hire vice presidents and others accordingly. 
 Your individual compensation package, as outlined below, includes a variety of features personally and professionally. Our overriding interest is to make sure you are
intensely focused on and rewarded for the company’s success. 
 The Compensation Package: 
 Your base starting salary will be at an annualized rate of Three Hundred Twenty Five Thousand Dollars ($325,000). Your salary level reviewed annually throughout your employment with the company during the
company’s regular performance review process. 
 In addition you will be eligible for an annual performance bonus. For the balance of the calendar year,
we have targeted that bonus at $75,000. Half of this bonus will be guaranteed and will be 

  

 111 HUNTINGTON AVE., 31ST
FLOOR,  •  BOSTON, MASSACHUSETTS 02199  •  PHONE (617) 425 9200  •  FAX (617) 425 9201 601
GATEWAY BLVD., SUITE 350  •  SOUTH SAN FRANCISCO, CALIFORNIA 94080  •  PHONE
(650) 553 3300  •  FAX (650) 553 3301 PRANNERSTRASSE 15  •  80333 MUNICH, GERMANY  •  PHONE +49 (0)
89 242147 0  •  FAX +49 (0) 89 242147 99 
 WWW.MPMCAPITAL.COM 

 
paid in January 2005, while the balance will be paid at the same time based upon, reaching certain mutually agreeable milestones which the Board and you will
set together. For the calendar year 2005, the bonus will be targeted at Forty Percent (40%) of base salary, based on the achievement of mutually agreed upon company-wide and individual performance goals. For the calendar year 2006, the bonus
will be targeted at Fifty Percent (50%) of base salary, based on the achievement of mutually agreed upon company-wide and individual performance goals. 
 Stock Options: 
 On the date you begin your employment, you will initially be granted immediately exercisable incentive stock options to purchase
Five Percent (5%) of Neuromed’s fully diluted stock including the anticipated second tranche of the $32 million Neuromed Series C financing. This option will vest in the following manner over a four year period commencing on your start
date. (i) Twenty Five Percent (25%) of this grant will be vested after twelve months and (ii) the balance of the grant will vest at the rate of 1/36 each month thereafter. The total vesting period for the grant is four years. The
stock will be priced at the Fair Market Value as determined by the Board of Directors at the time of the grant. At the last Board Meeting, the Board determined at that time the Fair Market Value was $0.10 per share. If exercised, the shares will be
held in escrow, and the unvested shares may be repurchased by the company upon termination. 
 In addition, you will be granted additional incentive stock
options upon achieving certain milestones mutually agreed to by the Board of Directors and yourself to be reached by the end of 2005 to purchase an additional Two Percent (2%) of Neuromed’s fully diluted stock based upon the anticipated
second tranche of the Series C financing. These options will vest at a rate of 1/30 each month and will be granted at the Fair Market Value as determined by the Board of Directors. 
 These options will contain appropriate death and disability provisions including a provision for continued salary and for exercising options for 90 days post death or disability. 
 In addition to the foregoing stock options, you will be eligible to receive additional stock options to be granted from time–to–time at the discretion of the
Board of Directors. 
 You may also participate in Neuromed’s standard employee benefits program, to the extent permissible under the relevant plans.

 Your employment at Neuromed is “at will”. The company will provide a separation, clause agreement that if you are terminated for any reason
other than misconduct or if you resign for good reason (as both will be defined in the separation agreement) you will be entitled to continuation of twelve months of salary plus a payment of the annual bonus payment earned in the preceding year.

 50% of the unvested stock options granted hereunder, will have a Change in Control provision which shall stipulate that
if there is a change in control of the ownership of the company via a merger, acquisition or similar combination and you do not continue thereafter to have similar compensation, which shall not be reduced or responsibilities in the company or you
are required to move your office more than fifty (50) miles from its location prior to such change, this portion will have their remaining vesting schedule accelerated so that these stock options are fully vested—a so called double trigger
clause. The remaining 50% of the unvested stock options granted hereunder, will have a Change in Control provision which shall stipulate that if there is a change in control of the ownership of the company via a merger, acquisition or similar
combination, this portion will have their remaining vesting schedule accelerated so that these stock options are fully vested—a so called single trigger clause. 
 Your right to receive accelerated vesting and severance payments pursuant to the preceding two paragraphs shall be subject to the condition that you execute a full release and waiver of all claims against the company
and related parties, in a customary form reasonably acceptable to the company. 
 You will be required to sign a confidentiality agreement, which will
include provisions relating to confidentiality of certain information, ownership of inventions, and restrictions on certain activities in order to protect the company’s confidential information, trade secrets and goodwill. 
 You will be allowed to serve on two not-for-profits Board of Directors and one for-profit Board of Directors as long as the for-profit Board is not in a competitive
field upon disclosure to the Board of the entities. 
 This letter constitutes our entire offer regarding the terms and conditions of your prospective
employment with Neuromed and will be the basis for an Employment contract between you and Neuromed which will incorporate these agreements into a formal contract. This offer will expire if not accepted by May 30, 2004. The precise start date
will be mutually agreed to, however we would like to move ahead as soon as practical. We look forward to receiving your signed acceptance of this offer prior to May 30. 
 Let us reiterate once more that we have high regards for your talents and abilities. We are excited about you leading Neuromed into the future and creating substantial value in the company. 
  

	
	All the best,
	
	/s/ Kurt C. Wheeler
	Kurt C. Wheeler
	For the Board of Directors of Neuromed

	
	Chairman, Neuromed CEO Search Committee

  

	CC.	Neuromed Board of Directors 

  

	
	Accepted:
	
	/s/ Christopher C. Gallen, MD, PhD
	 Christopher C. Gallen, MD, PhD

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}]]